Key result
Regular aspirin use in women was associated with a 27% lower risk of Barrett's esophagus ≥1 cm compared to non-regular use (OR 0.73).
Why the study?
Does aspirin use reduce the risk of Barrett's esophagus in women?
Does aspirin use reduce the risk of Barrett's esophagus in women?
Odds Ratio: 0.73 (95% CI 0.56–0.96)
This is the authors' abstract. We don't add key points for this paper.
Aspirin use is associated with reduction of esophageal adenocarcinoma but it is not known if it does so by preventing the development of Barrett's esophagus or by reducing neoplastic progression in patients with Barrett's esophagus. There is sparse literature to support the former assumption especially in women. This study by Jovani et al. based on Nurses' Health Study reports 27% lower risk of Barrett's esophagus among women using aspirin. The protective effect seems to increase with higher frequency and longer duration of aspirin use. This study provides evidence for lower prevalence of Barrett's esophagus in female aspirin users.
Aspirin use is associated with a 27% lower risk of Barrett's esophagus in women, with the protective effect increasing with higher frequency and longer duration of use.
No takes yet. Share an insight, caveat, or question.
Prashanthi N. Thota (2018) conducted an editorial in Barrett's esophagus (n=27,881). Aspirin use vs. Non-regular users was evaluated on Barrett's esophagus ≥1 cm (OR 0.73, 95% CI 0.56-0.96). Regular aspirin use in women was associated with a 27% lower risk of Barrett's esophagus ≥1 cm compared to non-regular use (OR 0.73).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: